In the Study of Tirzepatide in Participants with Heart Failure with Preserved Ejection Fraction with Obesity (SUMMIT) trial, tirzepatide significantly reduced the risk of death from cardiovascular causes or worsening heart failure events in patients with heart failure with preserved ejection fraction (ejection fraction 50% and above) and obesity (BMI 30 kg/m 2 ), compared with placebo (HR 0.62
Pi-Sunyer, X., Astrup, A., Fujioka, K., et al
Brandclub - Get rewarded to shop You need to enable JavaScript to run this app.
population, may limit generalizability
It is important to keep in mind that people taking GLP-1 medications may already be at risk of developing SIBO for other reasons
Choose WeightWatchers only if the WW program Points, Workshops, Connect, dietitians, or the WW-branded Clinic ecosystem is the deciding factor